Acutaas Chemicals Limited announced its unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025. The Board of Directors approved the results on January 28, 2026. Consolidated revenue from operations stood at ₹393.18 million for the quarter and ₹906.61 million for the nine-month period. Standalone revenue was ₹390.86 million for the quarter and ₹902.02 million for the nine months ended December 31, 2025.
Financial Performance Overview
Acutaas Chemicals Limited has released its unaudited financial results for the third quarter (Q3) and the nine months ended December 31, 2025. The results, approved by the Board of Directors on January 28, 2026, highlight the company’s financial standing.
Consolidated Financial Highlights
The consolidated financial results show the following:
- Revenue from operations for Q3 stood at ₹393.18 million, compared to ₹306.19 million for Q3 of the previous year.
- Total Income for Q3 reached ₹397.88 million.
- Revenue from operations for the nine months ended December 31, 2025, was ₹906.61 million.
- Net profit for the nine months reached ₹222.09 million.
Standalone Financial Highlights
The standalone financial results reported are:
- Revenue from operations for Q3 was ₹390.86 million, compared to ₹305.19 million for the same period last year.
- Total Income for the quarter stood at ₹397.20 million.
- Revenue from operations for the nine months ended December 31, 2025, reached ₹902.02 million.
- Net profit for the nine months was ₹229.10 million.
Equity and EPS
The earnings per share (EPS) stood at ₹13.19 basic and ₹13.10 diluted for the quarter ended December 31, 2025.
Sub-division/Split of Equity Shares
The Board approved a sub-division/split of each equity share from a face value of ₹10 to ₹5 in March 2025, effective from April 25, 2025.
Investment in Indichem Inc.
Acutaas Advance Material Limited (AAML), a subsidiary, invested approximately ₹130.80 million in Indichem Inc., a South Korean company, effectively from June 27, 2025.
Source: BSE
